Recent data reveals that more Americans are surviving cancer than ever before, reflecting decades of research, early detection, and advanced treatments.
A recent report from the American Cancer Society reveals a significant evolution in cancer survival trends throughout the United States. The annual update, released on January 13, indicates that nearly seven out of ten patients now live at least five years after receiving a cancer diagnosis. This rate marks a substantial rise compared with the mid-1970s, when only about half of those diagnosed reached that same point. The findings draw on data from cases identified between 2015 and 2021, and the five-year survival threshold continues to serve as a key indicator for evaluating advances against the disease.
The report also underscores a continued decline in cancer mortality rates through 2023, estimating that nearly 4.8 million deaths have been prevented since 1991. Researchers attribute this decline to reductions in smoking, earlier and more precise detection, and improvements in treatment strategies. Rebecca Siegel, lead author of the report and senior scientific director of surveillance research at the American Cancer Society, emphasized that these outcomes reflect the long-term impact of sustained cancer research efforts. She described the progress as a transformation of many cancers from once-lethal diagnoses into manageable or chronic conditions.
The influence of genetics and the impact of targeted therapies
Advances in understanding the genetic underpinnings of cancer have been a key driver of improved survival rates. Dr. Leonard Kalman, executive deputy director and chief medical officer at Miami Cancer Institute, explains that identifying specific genetic mutations in tumors allows physicians to apply precision medicine techniques. “When a mutation is identified, we can often match it with a targeted therapy that either cures patients or extends remission periods,” Kalman noted. This personalized approach is helping to turn previously fatal cancers into conditions that can be treated effectively over time, improving both longevity and quality of life for many patients.
Targeted treatments have become more prevalent for cancers including breast, colorectal, and lung cancers, as molecular profiling increasingly informs therapeutic choices. Researchers are also broadening the application of immunotherapy, which engages the body’s immune defenses to attack cancer cells, along with combination therapies that integrate conventional chemotherapy or radiation with newer pharmaceutical options. Together with early detection enabled by screening initiatives, these approaches have driven the notable improvements in survival highlighted in the report.
Significant gains in survival rates among cancers with historically high mortality
Although overall survival gains are substantial, the most dramatic progress has emerged in cancers once linked to very low survival prospects. Five-year survival for multiple myeloma, a type of bone marrow cancer, has climbed from 32% to 62%. Liver cancer survival has risen from 7% to 22%, and lung cancer rates have advanced from 15% to 28%. These shifts highlight how scientific breakthroughs and public health efforts focused on prevention, timely diagnosis, and effective care have reshaped outcomes.
Despite these positive trends, experts caution that challenges remain. Dr. Sara Myers, a breast cancer surgeon and leader of the BRIDGE program at The Ohio State University Comprehensive Cancer Center, noted that while the results are encouraging, significant disparities persist in access to care and screening. “It’s vital to ensure that patients not only receive effective treatment but also maintain a good quality of life, minimizing severe side effects,” Myers said. She emphasized that equitable access to care and supportive services remains critical for continuing the upward trend in survival.
Persistent challenges and disparities
Cancer continues to be a leading cause of death in the United States, and certain forms remain particularly deadly. Lung cancer is projected to account for the most cancer-related deaths in 2026, surpassing the combined fatalities from colorectal and pancreatic cancers. Additionally, the incidence of common cancers, including breast and prostate cancer, continues to rise, underscoring the need for ongoing prevention and early detection efforts.
Socioeconomic, racial, and ethnic inequities still shape outcomes, as underserved groups frequently face postponed diagnoses and constrained access to advanced therapies. Funding for cancer research, long backed by the federal government, has seen cuts that jeopardize the continuity of current investigations and the creation of future treatments. Shane Jacobson, CEO of the American Cancer Society, cautioned that declines in research financing and health insurance availability could hinder progress and slow upcoming breakthroughs.
Dr. Kalman echoed concerns about funding cuts, noting the decades of investment that have finally begun to yield tangible results in patient survival. “To see this progress now potentially compromised is deeply concerning,” he said. The continued support of research initiatives and equitable healthcare policies remains essential to ensure that recent gains in survival are not reversed.
Ongoing advancement and optimism
Despite these challenges, the overall trajectory remains positive. Innovations in genetic research, targeted therapies, immunotherapy, and improved public health measures are expected to drive further improvements in cancer outcomes. Increasing awareness about preventive measures, including smoking cessation, healthy diet, regular screenings, and vaccination against cancer-causing viruses, also contributes to better long-term results.
The report emphasizes that the battle against cancer remains ongoing, noting that sustained research funding, broader availability of advanced therapies, and efforts to reduce inequities are vital for continued advancement. For patients and families impacted by the disease, the trends presented in the American Cancer Society report provide encouragement, showing that survival is becoming more achievable and that cancer is increasingly manageable as a long-term condition.
The new findings reflect decades of dedication by researchers, clinicians, and public health advocates to improve cancer outcomes in the United States. With continued investment, innovation, and equitable healthcare access, survival rates are likely to improve further, offering renewed optimism to patients, families, and healthcare providers nationwide.
